Data Insights

BLM-07D1 by Systimmune for Metastatic Ovarian Cancer: Likelihood of Approval

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-07D1 in Metastatic Ovarian Cancer

Data Insights

BLM-07D1 by Systimmune for Endometrial Cancer: Likelihood of Approval

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-07D1 in Endometrial Cancer

Data Insights

BLM-07D1 by Systimmune for Cervical Cancer: Likelihood of Approval

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-07D1 in Cervical Cancer

Data Insights

Emfizatamab by Systimmune for Non-Hodgkin Lymphoma: Likelihood of Approval

Emfizatamab is under clinical development by Systimmune and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Emfizatamab in Non-Hodgkin Lymphoma

Data Insights

BLM-07D1 by Systimmune for Gynecological Cancer: Likelihood of Approval

BLM-07D1 is under clinical development by Systimmune and currently in Phase II for Gynecological Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-07D1 in Gynecological Cancer

Data Insights

Danvilostomig by Systimmune for Gastrointestinal Tumor: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Gastrointestinal Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Gastrointestinal Tumor

Data Insights

Danvilostomig by Systimmune for Metastatic Colorectal Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Metastatic Colorectal Cancer

Data Insights

Danvilostomig by Systimmune for Esophageal Cancer: Likelihood of Approval

Danvilostomig is under clinical development by Systimmune and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Esophageal Cancer

Data Insights

Izalontamab by Systimmune for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

GNC-035 by Systimmune for Non-Hodgkin Lymphoma: Likelihood of Approval

GNC-035 is under clinical development by Systimmune and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - GNC-035 in Non-Hodgkin Lymphoma

Data Insights

Izalontamab by Systimmune for Lung Adenocarcinoma: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Lung Adenocarcinoma

Data Insights

Izalontamab by Systimmune for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oral Cavity (Mouth) Cancer

Data Insights

Izalontamab by Systimmune for Oropharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oropharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Nasopharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Laryngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Laryngeal Cancer

Data Insights

Izalontamab by Systimmune for Hypopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Hypopharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Colon Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Colon Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Colon Cancer

Data Insights

Izalontamab by Systimmune for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Triple-Negative Breast Cancer (TNBC)

Data Insights

BLM-02D1 by Systimmune for Solid Tumor: Likelihood of Approval

BLM-02D1 is under clinical development by Systimmune and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-02D1 in Solid Tumor

Data Insights

BLM-02D1 by Systimmune for Gastrointestinal Tumor: Likelihood of Approval

BLM-02D1 is under clinical development by Systimmune and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BLM-02D1 in Gastrointestinal Tumor